CD47 is immunoglobulin and supramolecular complex composed of integrins, G protein, and cholesterol. It mediates a series of processes such as cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis, and inhibition of NO signalling. In recent years, CD47 also called the “don’t eat me” signal, has been highly expressed on the surface of various cancers, initiating an inhibitory signalling pathway that prevents cancer cells from phagocytosis by macrophages.
The factors driving the growth of the CD47 targeting therapeutics market include the rising developments in the CD47-targeting anti-cancer therapies, growing demand for cost-efficient cancer treatments, increasing government initiatives for cancer awareness, and R&D initiatives by market players for launching effective cancer therapies, and the growing number of cancer cases worldwide. According to the NCI (National Cancer Institute), cancer is among the leading causes of death worldwide. By 2040, more cancer cases are expected to rise to 29.5 million per year and cancer-related deaths to 16.4 million. Recently, the American FDA has granted orphan drug designation ("ODD") to ALX Oncology's next-generation CD47 blocker ‘evorpacept’ for treating patients with gastroesophageal junction cancer and gastric cancer. Thus, the increasing prevalence of cancer is projected to surge the demand for advanced cancer therapies to treat cancer patients effectively, which will likely fuel the market growth over the forecast period. However, the high R&D cost of target therapies and side effects associated with these therapies are expected to hamper the market’s growth in the coming years.
The CD47 targeting therapeutics market is classified based on target disease indication, type of molecule, and region. The target disease indication, segment the market into acute myeloid leukemia, non-hodgkin lymphoma, colorectal cancer, diffuse large B-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral mucositis, small cell lung cancers, and other disease indications. The acute myeloid leukaemia segment is anticipated to proliferate over the forecast period owing to the increased CD47 expression on human AML. The market is grouped into biologics and small molecules by type of molecule. Due to its increasing therapeutic applications, the biologics segment is expected to witness significant growth during the forecast years. Regionally, the market is considered across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.
North America is likely to witness the highest growth during the forecast period due to the high prevalence of cancer, growing demand for CD47 therapeutic products, and the increasing approvals for immunoglobulins.
Significant the key players operating in the CD47 targeting therapeutics market are Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others.
